|
[1]Lonardo A, Loria P, Adinolfi LE, et al.Hepatitis C and steatosis: a reappraisal[J]. J Viral Hepat, 2006, 13 (2) ∶73-80.
|
|
[2]Antn MD, RosellE, Gmez F, et al.Hepatic steatosis in chronic hepatitis C:study of risk factors and relationship with the fibrosis stage[J].Med Clin (Barc) , 2009, 132 (15) ∶574-579.
|
|
[3]Liakina V, SpeicienD, Irnius A, et al.Association of the preva-lence and grade of steatosis in patients with chronic hepatitis C with the host and viral factors[J].Acta Gastroenterol Belg, 2007, 70 (3) ∶260-266.
|
|
[4]koike K.Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection[J]. J Gastroenterol, 2009, 44 (suppl 19) ∶82-88.
|
|
[5]Wu CH, Tian GS, Wang QH, et al.Clinical features and prognosis of decompensated hepatitis C virus related cirrhosis[J]. zhonghua yi xue za zhi, 2008, 88 (8) ∶516-519.
|
|
[6]Takuma Y, Nouso K, Makino Y, et al.Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virusassociated hep-acellular carcinoma[J].Liver Int, 2007, 27 (5) ∶620-626.
|
|
[7]Sheikh MY, Choi J, Qadri l, et al.Hepatitis C virus infection:mo-lecular pathways to metabolic syndrome[J].Hepatology, 2008, 47 (6) ∶2127-2133.
|
|
[8]Mori Y, Moriishi K, Matsuura Y.Hepatitis C virus core protein:its coordinate roles with PA28gamma in metabolic abnormality and car-cinogenicity in the liver[J].Int J Biochem Cell Biol, 2008, 40 (8) ∶1437-1442.
|
|
[9]Akuta N, Suzuki F, Hirakawa M, et al.Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus[J]. J Med Virol, 2009, 81 (6) ∶1032-1039.
|
|
[10]Negro F, Sanyal AJ.Hepatitis C virus, Steatosis and lipid abnor-malities:clinical and pathogenic data[J].Liver Int, 2009, 29 (sup-pl2) ∶26-37.
|
|
[11]Koike K, Mivoshi H. Oxidative stress and hepatitis C viral infection[J]. Heoatol Res, 2006, 34 (2) ∶65-73.
|
|
[12]Rodriguez-Torres M, Govindarajan S, Diago M, et al. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks[J]. Liver Int, 2009, 29 (2) ∶237-241.
|
|
[13]Fierbinteanu -Braticevici C, Mohora M, Cretoiu D, et al.Role of oxidative stress in the pathogenesis of chronic hepatitis C (CHC) [J]. Rom J Morphol Embryol, 2009, 50 (3) ∶407-412.
|
|
[14]Esmat G, El Akel W, Metwally M, et al.Improvement of steatosis af-ter interferon therapy in HCV genotype4is related to weight loss[J].Indian J Gastroenterol, 2009, 28 (2) ∶45-48.
|
|
[15]Petta S, CammC, Di Marco V, et al.Time course of insulin resist-ance during antiviral therapy in non-diabetic, non-cirrhotic pa-tients with genotype1HCV infection[J].Antivir Ther, 2009, 14 (5) ∶631-639.
|
|
[16]Moriya K, Miyoshi H, Tsutsumi T, et al.Tacrolimus Ameliorates Metabolic Disturbance and Oxidative Stress Caused by Hepatitis C Virus Core Protein. Analysis Using Mouse Model and Cultured Cells[J]. Am J Pathol, 2009, 175 (4) ∶1515-1524.
|
|
[17]Pascual Pareja JF, Camino A, Larrauri J, et al.Factors associated with hepatic steatosis in human immunodeficiency virus and hepatits C virus coinfected patients[J]. Med Clin (Barc) , 2009, 132 (6) ∶208-213.
|
|
[18]Borghi V, Puoti M, Mussini C, et al.HIV coinfection and antiretro-viral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCVgenotype other than3[J].Anti-vir Ther, 2008, 13 (8) ∶1057-1065.
|
|
[19]Verma S, Goldin RD, Main J.Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection:is it associated with antiretroviral therapy and more advanced hepatic fibrosis-[J].BMC Res Notes, 2008, 1∶46.
|
DownLoad: